Advanced Materials for Cardiac Regeneration (AMCARE)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: European Comission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Cardiac Regeneration
  • Location: Europe


The Advanced Materials for Cardiac Regeneration (AMCARE) program, which will create 10 new positions, will carry out research to develop natural materials and new surgical devices to enhance the delivery of the body's own stem cells to the heart to promote healing after a heart attack (myocardial infarction) and prevent premature death. The therapies being developed will replace heart cells that die due to the reduced blood flow that occurs during a heart attack, with new healthy cells derived from stem cells that come from the patient's own bone marrow.


The AMCARE consortium aims to establish a translational research program to develop truly restorative therapies for acute myocardial infarction (MI) repair by optimizing cardiac progenitor cell (CPC) therapy using smart biomaterials and advanced drug delivery, and coupling these therapeutics with minimally invasive surgical devices. Two distinct biomaterial delivery systems for CPCs will be investigated in the AMCARE work program, including HA-based patches (CardioPatch) and HA-hydrogels (CardioGel). We also propose to develop two prototypes of new surgical devices (C-CathGel and SPREDS) that will ensure a minimally invasive delivery and fixation approach that are safe and effective for each therapeutic. The combinations of advanced material carriers and surgical devices will be assessed in a large animal model of acute-MI to best align our approach to clinical translation. The novel formulations and delivery methods will help post-MI patients in restoring cardiac function by targeting for repair the underlying myocardium damage, and could potentially decrease morbidity and mortality in the future. These goals will be achieved by integrating numerous areas of materials science and stem cell biology as well as leaders in the field of medical devices, biomaterials, and cardiovascular regeneration. We thus aim to improve long-term healthcare of European Union citizens by offering a revolutionary therapeutic modality for the treatment of acute-MI.

Consortium History

Launched: 11/01/2013
End date: 10/31/2017


Funded under FP7-NMP
Funding scheme: CP-TP - Collaborative Project targeted to a special group (such as SMEs)

Total cost:
EUR 8 694 507,6

EU contribution:
EUR 6 795 349

Other website

Points of Contact

Royal College of Surgeons in Ireland
Stephen's Green 123
Dublin, Ireland

Administrative contact: Garry Duffy
Tel.: +353879321479
Fax: +353 14022355

Sponsors & Partners

The College of the Holy & Undivided Trinity of Queen Elizabeth, Dublin

Contipro Biotech SRO, Czech Republic

Innova Spa, Italy

Adjucor GMBH, Germany

Cardio3 Biosciences SA, Belgium

Explora SRL, Italy

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V, Germany

Eberhard Karls Universitaet Tuebingen, Germany

Boston Scientific Ireland Limited, Ireland

Last Updated: 06/20/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.